Onco-Innovations Announces Private Placement
Onco-Innovations (OTCQB:ONNVF) announced a non-brokered private placement of up to 1,428,572 units at $1.40 per unit to raise up to $2,000,000. Each unit includes one common share and one-half of a warrant, with each whole warrant exercisable at $2.00 for 36 months. The company will issue Admin Fee Shares equal to 1.0% of shares sold and may pay finders' fees or issue finders' warrants on similar terms. Proceeds are for general corporate and R&D purposes. Closing is subject to regulatory approvals and issued securities carry a four-month-and-one-day hold. The company also appointed Christopher Gulka to the board, succeeding Graydon Bensler.
Onco-Innovations (OTCQB:ONNVF) ha annunciato un collocamento privato non intermediato di fino a 1.428.572 quote a $1,40 per quota per raccogliere fino a $2.000.000. Ogni quota comprende una azione ordinaria e la metà di un warrant, con ogni warrant intero esercitabile a $2,00 per 36 mesi. L'azienda emetterà azioni per oneri amministrativi pari al 1,0% delle azioni vendute e potrebbe pagare commissioni agli intermediari o emettere warrant agli intermediari su termini simili. I proventi sono destinati a scopi generali aziendali e a R&D. La chiusura è soggetta ad approvazioni normative e i titoli emessi comportano un vincolo di quattro mesi e un giorno. L'azienda ha inoltre nominato Christopher Gulka al consiglio, in sostituzione di Graydon Bensler.
Onco-Innovations (OTCQB:ONNVF) anunció una colocación privada no intermediada de hasta 1,428,572 unidades a $1.40 por unidad para recaudar hasta $2,000,000. Cada unidad incluye una acción común y la mitad de una warrant, y cada warrant completo es ejercitable a $2.00 durante 36 meses. La empresa emitirá Acciones de Tarifa Administrativa equivalentes al 1.0% de las acciones vendidas y puede pagar comisiones a los intermediarios o emitir warrants a los intermediarios en términos similares. Los ingresos serán para fines generales de la empresa y I+D. El cierre está sujeto a aprobaciones regulatorias y los valores emitidos llevarán un periodo de bloqueo de cuatro meses y un día. La empresa también nombró a Christopher Gulka al consejo, sucediendo a Graydon Bensler.
Onco-Innovations (OTCQB:ONNVF)은 최대 1,428,572개 유닛을 $1.40/유닛으로 비브로커(private) 방식으로 배정하여 최대 $2,000,000를 모금한다고 발표했습니다. 각 유닛은 보통주 1주와 워런트의 절반을 포함하며, 전체 워런트는 $2.00에 36개월 동안 행사할 수 있습니다. 회사는 판매 주식의 1.0%에 해당하는 관리 수수료 주식(Admin Fee Shares)을 발행하고 유사한 조건으로 중개인 수수료를 지급하거나 중개인 워런트를 발행할 수 있습니다. 조달액은 일반 기업 목적 및 R&D를 위한 것입니다. 마감은 규제 승인을 조건으로 하며 발행된 주식은 4개월 1일의 금지 기간을 갖습니다. 또한 회사는 Graydon Bensler를 대신하여 이사회에 Christopher Gulka를 임명했습니다.
Onco-Innovations (OTCQB:ONNVF) a annoncé une mise en place privée non intermédiaire pouvant atteindre 1 428 572 unités à $1,40 par unité afin de lever jusqu'à $2 000 000. Chaque unité comprend une action ordinaire et la moitié d’un warrant, chaque warrant entier pouvant être exercé à $2,00 pendant 36 mois. La société émettra des Actions de Frais d’Administration équivalentes à 1,0% des actions vendues et peut payer des frais de courtage ou émettre des warrants de courtage selon des termes similaires. Les fonds sont destinés à des usages généraux de l’entreprise et à la R&D. La clôture est soumise à des approbations réglementaires et les valeurs émises comportent une période de blocage de quatre mois et un jour. La société a également nommé Christopher Gulka au conseil, succédant à Graydon Bensler.
Onco-Innovations (OTCQB:ONNVF) kündigte eine nicht vermittelte Privatplatzierung von bis zu 1.428.572 Einheiten zu $1,40 pro Einheit an, um bis zu $2.000.000 zu beschaffen. Jedes Paket beinhaltet eine Stammaktie und die Hälfte eines Warrants, wobei jeder vollständige Warrants zu $2,00 für 36 Monate ausübbar ist. Das Unternehmen wird Verwaltungsgebühr-Aktien in Höhe von 1,0% der verkauften Aktien ausgeben und kann Vermittlergebühren zahlen oder Vermittlers-Warrants zu ähnlichen Bedingungen ausgeben. Die Mittel dienen allgemeinen Unternehmenszwecken und F&E. Der Abschluss unterliegt behördlichen Genehmigungen, und emittierte Wertpapiere tragen eine Sperrfrist von vier Monate und einen Tag. Das Unternehmen hat außerdem Christopher Gulka in das Board berufen, als Nachfolger von Graydon Bensler.
Onco-Innovations (OTCQB:ONNVF) أعلنت عن طرح خاص غير وسيط حتى 1,428,572 وحدة بسعر $1.40 للوحدة لجمع ما يصل إلى $2,000,000. كل وحدة تتضمن سهماً عادياً ونصف سند warrants، وكل warrant كامل قابلة للممارسة مقابل $2.00 لمدة 36 شهراً. ستصدر الشركة أسهماً مقابل أتعاب إدارية تعادل 1.0% من الأسهم المباعة وقد تدفع عمولات للمستشارين أو تصدر warrants للمستشارين بشروط مماثلة. العائدات مخصصة لأغراض الشركة العامة والبحث والتطوير. الإغلاق مشروط بالموافقات التنظيمية وتحمل الأوراق المالية المصدرة قيد حظر لمدة أربعة أشهر ويوم واحد. كما عينت الشركة كريستوفر جولكا في المجلس، خلفاً لـ Graydon Bensler.
Onco-Innovations (OTCQB:ONNVF) 宣布了一项非经纪人私募发行，最多可达 1,428,572份单位，每单位 $1.40，以筹集最多 $2,000,000。每单位含一股普通股和半个认股权证，整份认股权证可在 $2.00 下行使，期限为 36 个月。公司将发行等同于所售股票 1.0% 的管理费股票，并可能支付给中介费或按类似条款发行中介认股权证。收益将用于公司一般目的及研发。成交须经监管批准，发行证券附带一个 四个月零一日的禁售期。公司还任命 Christopher Gulka 入董事会，接替 Graydon Bensler。
- $2.0M gross proceeds targeted from the private placement
- Each unit includes a warrant exercisable at $2.00 for 36 months
- Appointment of Christopher Gulka with 30+ years of capital markets experience
- Issuance of up to 1,428,572 shares will dilute existing shareholders
- Admin Fee Shares equal to 1.0% of placed shares add further dilution
- Private placement restricted from U.S. sales; limits investor pool
- Issued securities subject to a 4 months + 1 day hold period
Not for distribution to United States wire services or for dissemination in the United States
VANCOUVER, BC, BC / ACCESS Newswire / October 14, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") of up to 1,428,572 units of the Company (the "Units") at a price of
The Company also intends to issue Shares equal to
In connection with the Private Placement, the Company may pay finders' fees and/or issue finders' warrants on the same terms as the Warrants, to eligible parties who have assisted by introducing subscribers to the Private Placement.
Closing of the Private Placement is subject to certain conditions, including, but not limited to, the receipt of all necessary regulatory and other approvals. All securities issued pursuant to Private Placement will be subject to a hold period of four months and one day pursuant to applicable securities laws. The Company intends to use the proceeds of the Private Placement for general corporate and working capital purposes, including in pursuit of the Company's operational and research and development objectives and for investor relations purposes.
The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and may not be offered or sold in the United States absent registration or available exemptions from such registration requirements. This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States, or in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The Company also announces the appointment of Mr. Christopher Gulka as a member of the Board of Directors, effective immediately. Mr. Gulka brings over 30 years of experience in capital and public markets. He founded Working Capital Corporation, a corporate finance firm specializing in valuations, due diligence, and management consulting. He previously served as CFO and Director of Inner Spirit Holdings Ltd. and has held senior financial and board roles with several public companies across the mining, energy, cannabis, and industrial sectors. He holds a Bachelor of Commerce (with Distinction) from the University of Alberta and is both a Chartered Financial Analyst (CFA) and Chartered Professional Accountant (CPA). Mr. Gulka succeeds Mr. Graydon Bensler on the Board. The Company thanks Mr. Bensler for his valuable contributions and dedicated service.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE has not reviewed and does not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Private Placement generally, and the anticipated use of funds and closing date thereof, as well as to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to complete the Private Placement as contemplated, or at all, that the anticipated proceeds may be lower than expected, the failure to receive regulatory approval in respect of the Private Placement, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward- looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
How much is Onco-Innovations (ONNVF) raising in the October 2025 private placement?
What are the unit terms in Onco-Innovations' private placement (ONNVF)?
How will the ONNVF private placement affect shareholder dilution?
When can holders of ONNVF securities from the private placement trade them?
Who is Christopher Gulka and what is his role at Onco-Innovations (ONNVF)?
Will Onco-Innovations (ONNVF) pay finders' fees for the private placement?
